This company listing is no longer active
WBIO Stock Overview
Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, Australia, and Latin America.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wockhardt Bio AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF0.02 |
| 52 Week High | CHF3.98 |
| 52 Week Low | CHF0.01 |
| Beta | 18.28 |
| 1 Month Change | -99.50% |
| 3 Month Change | n/a |
| 1 Year Change | -98.75% |
| 3 Year Change | -93.75% |
| 5 Year Change | n/a |
| Change since IPO | -99.60% |
Recent News & Updates
Shareholder Returns
| WBIO | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | 18.0% | -0.9% |
| 1Y | -98.8% | 21.6% | -2.9% |
Return vs Industry: WBIO underperformed the Swiss Biotechs industry which returned -34.2% over the past year.
Return vs Market: WBIO underperformed the Swiss Market which returned 3.4% over the past year.
Price Volatility
| WBIO volatility | |
|---|---|
| WBIO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: WBIO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine WBIO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | n/a | www.wockhardtbio.com |
Wockhardt Bio AG, together with its subsidiaries, develops, manufactures, and markets pharmaceutical and bio-pharmaceutical formulations in the United States, the United Kingdom, Ireland, Australia, and Latin America. Its products cover various therapeutic categories, including central nervous system agents, hormones and related agents, cardiovascular agents, anti-infective agents, and respiratory agents, as well as other agents, such as gastrointestinal, dermatological, and biological (vaccines) agents. The company is based in Zug, Switzerland.
Wockhardt Bio AG Fundamentals Summary
| WBIO fundamental statistics | |
|---|---|
| Market cap | CHF1.04m |
| Earnings (TTM) | -CHF2.62m |
| Revenue (TTM) | CHF262.46m |
0.0x
P/S Ratio-0.4x
P/E RatioIs WBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WBIO income statement (TTM) | |
|---|---|
| Revenue | US$297.12m |
| Cost of Revenue | US$133.64m |
| Gross Profit | US$163.48m |
| Other Expenses | US$166.45m |
| Earnings | -US$2.97m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 55.02% |
| Net Profit Margin | -1.00% |
| Debt/Equity Ratio | 21.1% |
How did WBIO perform over the long term?
See historical performance and comparison